Skip to main content

Mya Thomae, Harjit Kullar

Transgenomic has elected Mya Thomae to its board of directors. She is currently vice president of regulatory affairs at Illumina. Before that, she served as CEO of Myraqa, a diagnostics regulatory consulting firm, which was acquired by Illumina in 2014.

Transgenomic has also appointed Harjit Kullar vice president of marketing for biomarker discovery and genetic assays and platforms. He previously was content marketing leader for cross-functional global digital and web-based initiatives at Bio-Rad. Before that, he was director of product marketing, genomics, at Thermo Fisher Scientific.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.